Embecta (EMBC) Stock Forecast, Price Target & Predictions
EMBC Stock Forecast
Embecta stock forecast is as follows: an average price target of $23.00 (represents a 16.04% upside from EMBC’s last price of $19.82) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
EMBC Price Target
The average price target for Embecta (EMBC) is $23.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $26.00 to $20.00. This represents a potential 16.04% upside from EMBC's last price of $19.82.
EMBC Analyst Ratings
According to 2 Wall Street analysts, Embecta's rating consensus is 'Buy'. The analyst rating breakdown for EMBC stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Embecta Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 02, 2024 | Kallum Titchmarsh | Morgan Stanley | $20.00 | $20.68 | -3.29% | 0.91% |
| Nov 27, 2024 | Marie Thibault | BTIG | $26.00 | $19.80 | 31.31% | 31.18% |
| Jul 15, 2024 | Kallum Titchmarsh | Morgan Stanley | $12.00 | $13.17 | -8.88% | -39.46% |
| Aug 16, 2022 | Morgan Stanley | $36.00 | $33.42 | 7.72% | 81.63% |
The latest Embecta stock forecast, released on Dec 02, 2024 by Kallum Titchmarsh from Morgan Stanley, set a price target of $20.00, which represents a -3.29% decrease from the stock price at the time of the forecast ($20.68), and a 0.91% increase from EMBC last price ($19.82).
Embecta Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 2 | 3 |
| Avg Price Target | $23.00 | $23.00 | $19.33 |
| Last Closing Price | $19.82 | $19.82 | $19.82 |
| Upside/Downside | 16.04% | 16.04% | -2.47% |
In the current month, the average price target of Embecta stock is $23.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 16.04% increase as opposed to Embecta's last price of $19.82. This month's average price target is down 0.00% compared to last quarter, and up 18.99% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 02, 2024 | Morgan Stanley | Underweight | Overweight | Upgrade |
| Nov 27, 2024 | BTIG | Buy | Upgrade | |
| Jul 15, 2024 | Morgan Stanley | Underweight | Underweight | Hold |
| May 15, 2023 | Morgan Stanley | Underweight | Underweight | Hold |
| Jun 21, 2022 | Bank of America Securities | Underperform | Initialise |
Embecta's last stock rating was published by Morgan Stanley on Dec 02, 2024. The company Upgrade its EMBC rating from "Underweight" to "Overweight".
Embecta Financial Forecast
Embecta Revenue Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $277.30M | $281.90M | - | $277.10M | $275.70M | $274.60M | $291.10M |
| Avg Forecast | $283.29M | $280.65M | $277.44M | $272.03M | $281.87M | $279.17M | $281.10M | $277.25M | $276.97M | $267.44M | $264.70M | $264.92M | $271.55M | $275.07M | $262.88M | $262.90M | $261.01M | $276.86M |
| High Forecast | $283.29M | $280.65M | $277.44M | $272.03M | $281.87M | $279.17M | $281.10M | $277.25M | $278.09M | $267.44M | $264.70M | $264.92M | $272.73M | $275.07M | $262.88M | $262.90M | $261.01M | $276.86M |
| Low Forecast | $283.29M | $280.65M | $277.44M | $272.03M | $281.87M | $279.17M | $281.10M | $277.25M | $275.84M | $267.44M | $264.70M | $264.92M | $270.38M | $275.07M | $262.88M | $262.90M | $261.01M | $276.86M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 1.04% | - | 1.05% | 1.05% | 1.05% | 1.05% |
Embecta's average Quarter revenue forecast for Mar 24 based on 1 analysts is $264.70M, with a low forecast of $264.70M, and a high forecast of $264.70M. EMBC's average Quarter revenue forecast represents a -4.55% decrease compared to the company's last Quarter revenue of $277.30M (Dec 23).
Embecta EBITDA Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $45.50M | $44.40M | - | $59.30M | $88.90M | $53.20M | $102.20M |
| Avg Forecast | $113.09M | $112.04M | $110.76M | $108.60M | $112.52M | $111.45M | $112.22M | $110.68M | $110.57M | $106.77M | $105.67M | $105.76M | $108.41M | $109.81M | $104.95M | $104.95M | $104.00M | $110.32M |
| High Forecast | $113.09M | $112.04M | $110.76M | $108.60M | $112.52M | $111.45M | $112.22M | $110.68M | $111.02M | $106.77M | $105.67M | $105.76M | $108.88M | $109.81M | $104.95M | $104.95M | $104.00M | $110.32M |
| Low Forecast | $113.09M | $112.04M | $110.76M | $108.60M | $112.52M | $111.45M | $112.22M | $110.68M | $110.12M | $106.77M | $105.67M | $105.76M | $107.94M | $109.81M | $104.95M | $104.95M | $104.00M | $110.32M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.43% | 0.41% | - | 0.57% | 0.85% | 0.51% | 0.93% |
1 analysts predict EMBC's average Quarter EBITDA for Mar 24 to be $105.67M, with a high of $105.67M and a low of $105.67M. This is 132.24% upper than Embecta's previous annual EBITDA (Dec 23) of $45.50M.
Embecta Net Income Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $20.10M | $6.00M | - | $14.00M | $35.20M | $-17.20M | $62.40M |
| Avg Forecast | $31.55M | $31.18M | $28.85M | $27.58M | $31.52M | $34.01M | $33.43M | $32.51M | $20.94M | $26.84M | $23.14M | $26.32M | $22.99M | $26.61M | $27.96M | $29.50M | $34.51M | $50.32M |
| High Forecast | $31.55M | $31.18M | $28.85M | $27.58M | $31.52M | $34.01M | $33.43M | $32.51M | $30.88M | $26.84M | $23.14M | $27.49M | $27.02M | $26.61M | $27.96M | $29.50M | $34.51M | $50.32M |
| Low Forecast | $31.55M | $31.18M | $28.85M | $27.58M | $31.52M | $34.01M | $33.43M | $32.51M | $15.70M | $26.84M | $23.14M | $25.15M | $21.27M | $26.61M | $27.96M | $29.50M | $34.51M | $50.32M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.76% | 0.26% | - | 0.50% | 1.19% | -0.50% | 1.24% |
Embecta's average Quarter net income forecast for Mar 24 is $23.14M, with a range of $23.14M to $23.14M. EMBC's average Quarter net income forecast represents a 15.11% increase compared to the company's last Quarter net income of $20.10M (Dec 23).
Embecta SG&A Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $90.30M | $95.70M | - | $85.20M | $72.80M | $81.90M | $83.80M |
| Avg Forecast | $66.26M | $65.64M | $64.89M | $63.63M | $65.93M | $65.30M | $65.75M | $64.85M | $64.78M | $62.55M | $61.91M | $61.96M | $63.51M | $64.34M | $61.49M | $61.49M | $61.05M | $64.76M |
| High Forecast | $66.26M | $65.64M | $64.89M | $63.63M | $65.93M | $65.30M | $65.75M | $64.85M | $65.04M | $62.55M | $61.91M | $61.96M | $63.79M | $64.34M | $61.49M | $61.49M | $61.05M | $64.76M |
| Low Forecast | $66.26M | $65.64M | $64.89M | $63.63M | $65.93M | $65.30M | $65.75M | $64.85M | $64.52M | $62.55M | $61.91M | $61.96M | $63.24M | $64.34M | $61.49M | $61.49M | $61.05M | $64.76M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.46% | 1.51% | - | 1.39% | 1.18% | 1.34% | 1.29% |
Embecta's average Quarter SG&A projection for Mar 24 is $61.91M, based on 1 Wall Street analysts, with a range of $61.91M to $61.91M. The forecast indicates a -31.44% fall compared to EMBC last annual SG&A of $90.30M (Dec 23).
Embecta EPS Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $0.35 | $0.10 | - | $0.24 | $0.62 | $-0.30 | $1.08 |
| Avg Forecast | $0.55 | $0.54 | $0.50 | $0.48 | $0.55 | $0.59 | $0.58 | $0.56 | $0.36 | $0.46 | $0.40 | $0.46 | $0.40 | $0.46 | $0.48 | $0.51 | $0.60 | $0.87 |
| High Forecast | $0.55 | $0.54 | $0.50 | $0.48 | $0.55 | $0.59 | $0.58 | $0.56 | $0.53 | $0.46 | $0.40 | $0.48 | $0.47 | $0.46 | $0.48 | $0.51 | $0.60 | $0.87 |
| Low Forecast | $0.55 | $0.54 | $0.50 | $0.48 | $0.55 | $0.59 | $0.58 | $0.56 | $0.27 | $0.46 | $0.40 | $0.43 | $0.37 | $0.46 | $0.48 | $0.51 | $0.60 | $0.87 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.77% | 0.25% | - | 0.50% | 1.22% | -0.50% | 1.24% |
According to 1 Wall Street analysts, Embecta's projected average Quarter EPS for Mar 24 is $0.40, with a low estimate of $0.40 and a high estimate of $0.40. This represents a 14.29% increase compared to EMBC previous annual EPS of $0.35 (Dec 23).
Embecta Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AKYA | Akoya Biosciences | $2.54 | $4.83 | 90.16% | Buy |
| TFX | Teleflex | $178.28 | $254.50 | 42.75% | Buy |
| ANGO | AngioDynamics | $9.26 | $13.00 | 40.39% | Buy |
| BAX | Baxter | $29.64 | $39.00 | 31.58% | Hold |
| HAE | Haemonetics | $82.07 | $107.00 | 30.38% | Buy |
| ATRC | AtriCure | $31.50 | $39.67 | 25.94% | Buy |
| ATR | AptarGroup | $163.09 | $200.00 | 22.63% | Buy |
| COO | Cooper Companies | $94.49 | $115.00 | 21.71% | Buy |
| ALC | Alcon | $85.54 | $104.00 | 21.58% | Buy |
| ICUI | ICU Medical | $157.17 | $190.50 | 21.21% | Buy |
| WST | West Pharmaceutical Services | $334.26 | $393.00 | 17.57% | Buy |
| EMBC | Embecta | $19.82 | $23.00 | 16.04% | Buy |
| MMSI | Merit Medical Systems | $99.00 | $108.83 | 9.93% | Buy |
| NVST | Envista | $19.24 | $20.29 | 5.46% | Hold |
| RMD | ResMed | $242.62 | $233.50 | -3.76% | Hold |